 |
 Video: What is a Stock Split?
|
|
|
| Summit Therapeutics is holding company. Through its subsidiaries, Co. is a biopharmaceutical company focused on the discovery, development, and commercialization of medicinal therapies. Co.'s ivonescimab is a bispecific antibody that combines the benefits of immunotherapy via a blockade of PD-1 with the anti-angiogenesis benefits of an anti-vascular endothelial growth factor into a single molecule. Co. also focuses on ridinilazole, its product candidate for treating patients suffering from Clostridioides difficile infection. Co.'s other product candidate, SMT-738, is in development for combating multidrug resistant infections, specifically carbapenem-resistant Enterobacteriaceae infections. According to our Summit Therapeutics stock split history records, Summit Therapeutics has had 0 splits. | |
|
Summit Therapeutics (SMMT) has 0 splits in our Summit Therapeutics stock split history database.
Looking at the Summit Therapeutics stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Summit Therapeutics shares, starting with a $10,000 purchase of SMMT, presented on a split-history-adjusted basis factoring in the complete Summit Therapeutics stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
03/06/2015 |
|
| End date: |
04/26/2024 |
|
| Start price/share: |
$10.29 |
|
| End price/share: |
$3.86 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
-62.49% |
|
| Average Annual Total Return: |
-10.17% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$3,749.98 |
|
| Years: |
9.15 |
|
|
|
|
|
